The Daily Breeze |
Biotech explodes in LA County, tackling everything from sickle-cell anemia to spider-free silk
The Daily Breeze Biotech companies across Los Angeles County are unlocking new solutions for a host of as-yet-untreatable ailments, from sickle-cell anemia and rheumatoid arthritis to all varieties of cancers. But, in response to consumer demands for sustainable, ... |
Seeking Alpha |
3 Things In Biotech You Should Learn Today: July 22, 2017
Seeking Alpha Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest offering you some thoughts on recent news from the world of biotech and pharmaceutical science. Of course, "daily" is a loose descriptor, as you may have noticed ... |
Markets Insider |
A former biotech executive who's living with terminal cancer wants to reset expectations about new cancer treatments
Markets Insider In 2015, he was diagnosed with head and neck cancer, which was caused by human papillomavirus (or HPV), a sexually transmitted infection. After the diagnosis, Becker — who detailed his experience in "A Walk With Purpose: Memoir of a Bioentrepreneur" ... and more » |
Business Insider |
A former biotech executive who's living with terminal cancer wants to reset expectations about new cancer treatments
Business Insider In 2015, he was diagnosed with head and neck cancer, which was caused by human papillomavirus (or HPV), a sexually transmitted infection. After the diagnosis, Becker — who detailed his experience in "A Walk With Purpose: Memoir of a Bioentrepreneur" ... and more » |
Boston Business Journal |
Pharma giant Astellas joins biotech stampede into Cambridge
Boston Business Journal The Greater Boston market, and Cambridge in particular, has ranked as the top life sciences market in the world for years. Now there's another biotech company establishing a foothold in the city. Austin biotech company loses CEO as disease treatments work through regulatory processAustin Business Journal all 262 news articles » |
|
Biotech Bull is Back: 4 Keys to Play It
Zacks.com When I see a big company -- whether from traditional Pharma or Biotech -- team up with a little guy, I know something good is in the pipeline and I start paying more attention to that potential breakthrough. If "big brother" helps get my target through ... and more » |
|
3 Been-There-Done-That Biotech CEOs Who Are Doing it Again
Motley Fool You might want to turn back the clock so that you can profit from Puma Biotechnology's (NASDAQ:PBYI) 212% return this year, but unfortunately, you can't. Instead, you'll just have to go out and find the next big biotech winner -- and to manage that ... and more » |
|
3 Been-There-Done-That Biotech CEOs Who Are Doing it Again ...
Motley Fool After Puma Biotech's recent success, the search is on for other clinical-stage biotechs being run by proven CEOs. Could leadership experience turn Aurinia ... and more » |
|
Bone disease biotech Clementia Pharmaceuticals sets terms for $100 million IPO
Nasdaq Clementia Pharmaceuticals, a clinical-stage biotech focused on treating bone diseases, announced terms for its IPO on Friday. The Montreal, Canada-based company plans to raise $100 million by offering 7.2 million shares at a price range of $13 to $15. |
FierceBiotech |
News of Note—Biotech IPOs; CHMP knockbacks
FierceBiotech The CHMP said it didn't think Nektar has done enough to show the med works in this setting. CHMP decision (PDF). > While 2016 was pretty dire for IPOs, as we delve deeper into 2017 biotech public offerings are bouncing back, with two announced today. and more » |